Results of a small new trial performed in a pediatric gynecology clinic show that an endometriosis therapy previously studied only in adults may be effective for teens. The findings reflect outcomes for quality of life in adolescents treated with “add-back” therapy with norethindrone acetate (NA) plus conjugated estrogens (CEE) versus NA alone.
A meta-analysis of data from more than 17,000 cases of endometriosis suggest that specific genes involved in sex steroid hormone signaling and function may play a role in the disorder.
Retrospective analysis of data on women undergoing surgery for urinary tract endometriosis sheds new light on the role that the surgical team’s expertise has on patient outcome.
Readers discuss the prevalence of endometriosis and providing healthcare to the poor.
A genomic analysis of endometriotic lesions shows that a disease associated with almost no risk of malignant transformation may harbor mutations associated with cancer. The findings, published in NEJM, provide a rationale for characterizing all endometriosis subtypes, say the authors.
New research on two different dosages of elagolix show that both doses improved dysmenorrhea and nonmenstrual pelvic pain in women with endometriosis. The findings, published in NEJM, add to data from previous studies of the drug, which showed that it produced partial to nearly full estrogen suppression.
Researchers in France asked the question in a study using patient questionnaires.
Dyspareunia, urinary functional symptoms, and dysmenorrhea were found in 47% of the women in the study.
One study found advantages and drawbacks.
If you're observing it in your practice, you'll want to know about these resources.